TrialDiabetes, obesity & metabolism2020

Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.

Stefano Del Prato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.